Augmentation of clozapine with aripiprazole in severe psychotic bipolar and schizoaffective disorders: A pilot study

Clinical Practice and Epidemiology in Mental Health

Volumn 6, Issue , 2010, Pages 30-35

  Benedetti, Alessandra ^a   Di Paolo, Antonello ^a   Lastella, Marianna ^a   Casamassima, Francesco ^a   Candiracci, Chiara ^b   Litta, Antonella ^a   Ciofi, Laura ^a   Danesi, Romano ^a   Lattanzi, Lorenzo ^a   Del Tacca, Mario ^a   Cassano, Giovanni Battista ^a  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

Author keywords

Aripiprazole; Augmentation; Clozapine; Pharmacokinetic interactions; Psychotic bipolar disorder; Schizoaffective disorder

Indexed keywords

ARIPIPRAZOLE; CLOZAPINE; DELORAZEPAM; DULOXETINE; HALOPERIDOL; IMIPRAMINE; LITHIUM; NORCLOZAPINE; NORTRIPTYLINE; VALPROIC ACID;

ADD ON THERAPY; ADULT; ARTICLE; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; MANIC DEPRESSIVE PSYCHOSIS; PHARMACODYNAMICS; PILOT STUDY; RETROSPECTIVE STUDY; SCHIZOAFFECTIVE PSYCHOSIS; THOUGHT DISORDER; UNSPECIFIED SIDE EFFECT;

EID: 85047687079     PISSN: None     EISSN: 17450179     Source Type: Journal    
DOI: 10.2174/1745017901006010030     Document Type: Article

References (34)

1. Goodwin FK, Jamison KR, Eds. Manic-depressive illness. New York: Oxford University Press 1990.
2. Goldberg JF, Harron M, Eds. Bipolar disorders: clinical course and outcome. Washington, DC: American Psychiatric Press 1999.
3. Judd LL, Akiskal HS. The prevalence and disability of bipolar spectrum disorders in the U.S. population: re-analysis of the ECA database taking into account subthreshold cases. J Affect Disord 2003; 73: 123-31. (Pubitemid 36044640)
4. American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psych 2002;159 (suppl 4): 1-50.
5. Calabrese JR, Kimmel SE, Woyshville MJ, et al. Clozapine for treatment-refractory mania. Am J Psychiatry 1996; 153(6): 759-64. (Pubitemid 26170535)
6. Ciapparelli A, Dell'Osso L, Bandettini di Poggio A, et al. Clozapine in treatment-resistant patients with schizophrenia, schizoaffective disorder, or psychotic bipolar disorder: a naturalistic 48-month follow-up study. J Clin Psychiatry 2003; 64(4): 451-8. (Pubitemid 36547291)
7. Englisch S, Zink M. Combined antipsychotic treatment involving clozapine and aripiprazole. Prog Neuropsychopharmacol Biol Psychiatry 2008; 1; 32(6): 1386-92. (Pubitemid 352033663)
8. Nosè M, Accordini S, Artioli P, et al. Rationale and design of an independent randomised controlled trial evaluating the effectiveness of aripiprazole or haloperidol in combination with clozapine for treatment-resistant schizophrenia. Trials 2009; 15; 10:31.
9. Chang JS, Ahn YM, Park HJ, et al. Aripiprazole augmentation in clozapine-treated patients with refractory schizophrenia: an 8-week, randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2008; 69(5): 720-31. (Pubitemid 351838681)
10. Clarke LA, Lindenmayer JP, Kaushik S. Clozapine augmentation with aripiprazole for negative symptoms. J Clin Psychiatry 2006; 67, 4: 675-6. (Pubitemid 43764249)
11. Abu-Tair F, Kopitz J, Bergemann N. Clozapine Augmented With Aripiprazole in 5 Patients With Schizophrenia. J Clin Psychopharmacol 2006; 26(6): 669-71. (Pubitemid 44772751)
12. Rocha FL, Hara C. Benefits of combining aripiprazole to clozapine: three case reports. Prog Neuropsychopharmacol Biol Psychiatry 2006; 30(6): 1167-9. (Pubitemid 43964840)
13. Henderson DC, Kunkel L, Nguyen DD, et al. An exploratory open-label trial of aripiprazole as an adjuvant to clozapine therapy in chronic schizophrenia. Acta Psychiatr Scand 2006; 113(2): 142-7. (Pubitemid 43340908)
14. Ashton KA. Indexing of reports on aripiprazole augmentation of clozapine. J Clin Psychiatry 2007; 68(2): 334-5.
15. Ziegenbein M, Sieberer M, Calliess IT, Kropp S. Combination of clozapine and aripiprazole: a promising approach in treatment-resistant schizophrenia. Aust N Z J Psychiatry 2005; 39(9): 840-1. (Pubitemid 43904480)
16. Mitsonis CI, Dimopoulos NP, Mitropoulos PA, et al. Aripiprazole augmentation in the management of residual symptoms in clozapine-treated outpatients with chronic schizophrenia: An open-label pilot study. Prog Neuropsychopharmacol Biol Psychiatry 2007; 30; 31(2): 373-7. (Pubitemid 46210227)
17. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th edition. Washington DC: American Psychiatric Association 1994.
18. Ventura J, Nuechterlein KH, Subotnik KL, Gutkind D, Gilbert EA. Symptom dimensions in recent-onset schizophrenia and mania: a principal components analysis of the 24-item Brief Psychiatric Rating Scale. Psychiatry Research 2000; 97: 129-135. (Pubitemid 32126552)
19. Guy W, Bonato RR, Eds. Manual for the ECDEU Assessment Battery. 2. Rev ed. Chevy Chase, Md: National Institute of Mental Health; 1970: 12-1-12-6
20. Guy W. Dosage Record and Treatment Emergent Symptoms scale (DOTES). ECDEU assessment manual for psychopharmacology - revised. DHEW Publication No. ADM 76-338 1976: 223-244 US Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, NIMH Psychopharmacology Research Branch, Division of Extramural Research Programs Rockville, MD, 1976.
21. Kirschbaum KM, Muller MJ, Zernig G, et al. Therapeutic monitoring of aripiprazole by HPLC with column-switching and spectro-photometric detection. Clin Chem 2005; 51(9): 1718-21. (Pubitemid 41233111)
22. StataCorp, College Station, TX, USA 2004.
23. Hirose T, Kikuchi T. Aripiprazole, a novel antipsychotic agent: dopamine D2 receptor partial agonist. J Med Invest 2005; 52: 284-90. (Pubitemid 43051889)
24. Perry PJ, Miller DD, Arndt SV, Cadoret RJ. Clozapine and norclozapine plasma concentrations and clinical response of treatment-refractory schizophrenic patients. Am J Psychiatry 1991; 148(2): 231-5.
25. Zito JM, Volavka J, Craig TJ, Czobor P, Banks S, Vitrai J. Pharmacoepidemiology of clozapine in 202 inpatients with schizophrenia. Ann Pharmacother 1993; 27(10): 1262-9 (Pubitemid 23321976)
26. Potkin SG, Bera R, Gulasekaram B, et al. Plasma clozapine concentrations predict clinical response in treatment-resistant schizophrenia. J Clin Psychiatry (1994); 55 (Suppl B): 133-6. (Pubitemid 24353037)
27. Remington G, Saha A, Chong SA, Shammi C. Augmentation strategies in clozapine-resistant schizophrenia. CNS Drugs 2005; 19(10): 843-72. (Pubitemid 43140687)
28. Advokat C. Differential effects of clozapine versus other antipsychotics on clinical outcome and dopamine release in the brain. Essent Psychopharmacol 2005; 6(2): 73-90.
29. Hamamura T, Harada T. Unique pharmacological profile of aripiprazole as the phasic component buster. Psychopharmacology (Berl) 2007; 191(3): 741-3. (Pubitemid 46355901)
30. Grunder G, Carlsson A, Wong DF. Mechanism of new antipsychotic medications: occupancy is not just antagonism. Arch Gen Psychiatry 2003; 60: 974-7. (Pubitemid 37222078)
31. Kapur S, Seeman P. Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics? A new hypothesis. Am J Psychiatry 2001; 158: 360-9. (Pubitemid 32205190)
32. Karunakaran K, Tungaraza TE, Harborne GC. Is clozapinearipiprazole combination a useful regime in the management of treatment-resistant schizophrenia? J Psychopharmacol 2007; 21(4): 453-6. (Pubitemid 47077300)
33. Gao K, Kemp DE, Ganocy SJ, Gajwani P, Xia G, Calabrese JR. Antipsychotic-induced extrapyramidal side effects in bipolar disorder and schizophrenia: a systematic review. J Clin Psychopharmacol 2008; 28(2): 203-9. (Pubitemid 351417126)
34. Pacher P, Kecskemeti V. Cardiovascular Side Effects of New Antidepressants and Antipsychotics: New Drugs, old Concerns? Curr Pharm Des 2004; 10(20): 2463-2475. (Pubitemid 38997427)